ERBB2 and neoplasm: The odds ratio for treatment delay (45 days or more) was 0.87 for 2020 versus 2019 (95% CI, 0.5-1.53) and 0.9 for 2021 versus 2019 (95% CI, 0.52-1.55), after adjusting for type of POC, presentation with symptoms, treatment type, tumor stage, nodal stage, and EBC subtype (ie, luminal, HER2-positive, and triple-negative).